Cytotoxic Glucose Degradation Products in Fluids for Peritoneal Dialysis

Authors

  • Gloria Shalviri Adverse Drug Reaction Center, Food and Drug Deputy, Ministry of Health, Tehran, Iran.
  • Maral Shekarchi Food and Drug Lab Research Center, Ministry of Health, Tehran, Iran.
  • Maryam Imaninejad Food and Drug Lab Research Center, Ministry of Health, Tehran, Iran.
  • Maryam Shekarchi Food and Drug Lab Research Center, Ministry of Health, Tehran, Iran.
  • Noushin Adib Food and Drug Lab Research Center, Ministry of Health, Tehran, Iran.
Abstract:

During the standard heat sterilization process of the lactate–buffered peritoneal dialysis solutions, glucose (an osmotic active substance) degrades to form compounds called glucose degradation products which are cytotoxic and affect the survival of the peritoneal membrane. This case presentation is based on an observation of 224 aseptic peritonitis cases of unknown etiology. For the purpose of clarification, we analyzed the peritoneal dialysis solutions for the presence of acetaldehyde by using a developed and validated high-performance liquid chromatography (HPLC) pre-column derivitazation. The method was validated with respect to validation factors such as linearity, precision, recovery and (LOD). The acetaldehyde level of solutions before heat sterilization was 1.78 ± 2.7 ppm whereas in samples after heat sterilization was about 20 ± 2.07 ppm Based on the forementioned findings, we hypothesized that the higher levels of acetaldehyde and possibly the other glucose degradation products may have been an etiological factor in these 224 cases of chemical peritonitis. So it is important for the manufacturers to carefully review the heat of sterilization process in the production line.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

cytotoxic glucose degradation products in fluids for peritoneal dialysis

during the standard heat sterilization process of the lactate–buffered peritoneal dialysis solutions, glucose (an osmotic active substance) degrades to form compounds called glucose degradation products which are cytotoxic and affect the survival of the peritoneal membrane. this case presentation is based on an observation of 224 aseptic peritonitis cases of unknown etiology. for the purpose of...

full text

New pH-neutral peritoneal dialysis solution, low in glucose degradation products, in a double-chamber bag.

Fresenius Medical Care-North America has developed a neutral-pH version of its Delflex peritoneal dialysis (PD) solution with low glucose degradation products (GDPs): Delflex Neutral pH. The Delflex Neutral pH system stores the PD solution in a dual-chamber bag. The product is admixed by the patient before use. The new design facilitates GDP reduction in two ways. First, GDPs are reduced becaus...

full text

Peritoneal dialysis solutions low in glucose degradation products: clinical experience and outcomes.

The latest literature describing clinical experiences with peritoneal dialysis solutions low in glucose degradation products (GDPs) is mostly consistent with previous reports suggesting less inflammation, better peritoneal mesothelial mass preservation, a lower rate of decline of residual renal function, and improved patient survival. The data suggest stable peritoneal transport rates, but no d...

full text

Peritoneal dialysis patients with high effluent fibrin degradation products.

Encapsulating peritoneal sclerosis (EPS) is a major and fatal complication of peritoneal dialysis (PD). For treatment, the efficacies of steroids, tamoxifen, immunosuppressants, and surgical total intestinal enterolysis have been reported, but the results have not been sufficient. Because treatment after the onset of EPS is limited, a prophylactic therapy is needed. We previously reported that ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume Volume 10  issue Number 1

pages  113- 117

publication date 2010-12-13

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023